Pharmacokinetics of oxmetidine, a new histamine H2-receptor antagonist, after single oral and intravenous doses. 1983

K A Jönsson, and G Bodemar, and R Gotthard, and B Norlander, and A Walan

The plasma concentration curves and urinary excretion of oxmetidine after administration of single i.v. (100 mg) and oral (200 mg) doses have been studied in 11 patients with peptic ulcer disease. The mean bioavailability of the drug was 70% (range 53-91%). After intravenous administration, the mean plasma t 1/2 beta was 3.0 h, the mean apparent volume of distribution 0.7 l/kg, the mean total plasma clearance 12.3 l/h and the mean plasma renal clearance was 0.7 l/h. Following intravenous and oral administration an average of 6% and 3%, respectively, of unchanged drug was found in the urine. The plasma concentration curve after oral administration in most patients exhibited two maxima, with peak concentrations appearing between 45 and 210 min after dosing.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

K A Jönsson, and G Bodemar, and R Gotthard, and B Norlander, and A Walan
January 1985, International journal of clinical pharmacology research,
K A Jönsson, and G Bodemar, and R Gotthard, and B Norlander, and A Walan
November 1983, Deutsche medizinische Wochenschrift (1946),
K A Jönsson, and G Bodemar, and R Gotthard, and B Norlander, and A Walan
July 1984, Xenobiotica; the fate of foreign compounds in biological systems,
K A Jönsson, and G Bodemar, and R Gotthard, and B Norlander, and A Walan
February 1982, Gut,
K A Jönsson, and G Bodemar, and R Gotthard, and B Norlander, and A Walan
April 1999, Xenobiotica; the fate of foreign compounds in biological systems,
K A Jönsson, and G Bodemar, and R Gotthard, and B Norlander, and A Walan
June 1988, Journal of applied toxicology : JAT,
K A Jönsson, and G Bodemar, and R Gotthard, and B Norlander, and A Walan
January 1989, Scandinavian journal of gastroenterology. Supplement,
K A Jönsson, and G Bodemar, and R Gotthard, and B Norlander, and A Walan
March 1977, Ugeskrift for laeger,
K A Jönsson, and G Bodemar, and R Gotthard, and B Norlander, and A Walan
April 1988, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
K A Jönsson, and G Bodemar, and R Gotthard, and B Norlander, and A Walan
May 1986, Archives internationales de pharmacodynamie et de therapie,
Copied contents to your clipboard!